| ID | 67615 |
| フルテキストURL | |
| 著者 |
Yamashita, Masahiro
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Higo, Hisao
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Fujii, Nobuharu
Department of Hematology and Oncology, Okayama University Hospital
Kaken ID
publons
researchmap
Matsumoto, Chiaki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Makimoto, Go
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ninomiya, Kiichiro
Center for Comprehensive Genomic Medicine, Okayama University Hospital
Kaken ID
Fujii, Masanori
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Rai, Kammei
Center for Innovative Clinical Medicine, Okayama University Hospital
Ohashi, Kadoaki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
researchmap
Hotta, Katsuyuki
Center for Innovative Clinical Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
Maeda, Yoshinobu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
Miyahara, Nobuaki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
researchmap
|
| 抄録 | A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.
|
| キーワード | Chimeric antigen receptor-T cell therapy
Coronavirus disease 2019
Multidrug therapy
Organizing pneumonia
|
| 発行日 | 2024
|
| 出版物タイトル |
Respiratory Medicine Case Reports
|
| 巻 | 51巻
|
| 出版者 | Elsevier
|
| 開始ページ | 102104
|
| ISSN | 2213-0071
|
| 資料タイプ |
学術雑誌論文
|
| 言語 |
英語
|
| OAI-PMH Set |
岡山大学
|
| 著作権者 | © 2024 The Authors.
|
| 論文のバージョン | publisher
|
| DOI | |
| Web of Science KeyUT | |
| 関連URL | isVersionOf https://doi.org/10.1016/j.rmcr.2024.102104
|
| ライセンス | http://creativecommons.org/licenses/by-nc-nd/4.0/
|
